BioAtla’s strategy is to advance a large portfolio of CABs in a variety of formats that can be used individually and in combinations to best treat particular cancer indications. We are very selective in our partnerships and ideally will take our drug candidates through clinical proof of concept before partnering. Our relationship with Pfizer provides us with access to high quality ADC technology for our drugs. In addition, the companies are working together to advance a CAB immune checkpoint inhibitor and selected CAB-ADCs into commercial products and markets around the world. Similarly, our partnership with Sinobioway supports a comprehensive strategy to address the second largest pharmaceutical market in the world, China, while providing a continuous source of funding for the development of new drug candidates.
Beijing Sinobioway Group Company, Ltd was founded in 1992 and is one of the three main industrial groups affiliated with Peking University. Sinobioway is a leader in the development of the bioeconomy in China, including investments in biomedicine, bioagriculture, bioenergy, bioenvironment, bioservices, biomanufacturing and biointelligence. The development and commercialization of biologic therapeutics is a particular focus of Sinobioway, including the construction of a large biologics manufacturing facility in the new bio-economic zone in Hefei.
BioAtla® and Sinobioway have a strategic partnership to develop and commercialize select CAB antibodies and other CAB-based therapeutics for the Chinese market, helping to address the growing demand in China for innovative therapeutic products. For more information see News.